Clinical Trials Directory
We are doing this study to learn more about the connection between the brain and leg muscles in people who have chronic stroke. We want to understand how this connection affects the walking abilities of chronic stroke patients so we can provide better help to stroke patients who need to improve their motor function.
People in the study will have one visit that lasts about 20 minutes. During this visit, the researchers will ask for basic information like age, gender, and race or ethnicity. They will also look at skin color using a special chart called the Monk Skin Tone scale. Next, trained workers will use a small device called the InfraScanner 2500TM to check different parts of the head. These parts include the front, sides, and back. The device is safe, approved by the FDA, and does not use harmful radiation. It uses light to do its job and does not hurt. This study does not give medicine, does not pick people randomly, and does not share test results with the participants.
We are doing this study to find out if an experimental drug called PT217 (the study drug) is a safe and effective option for people who have neuroendocrine carcinomas. We want to see how this drug works when it is given on its own and in combination with standard chemotherapy and/or immunotherapy drugs.
If you join this research registry, you will be asked to fill out short surveys that take about 10 to 15 minutes each time. These surveys will be done at several times, including your first doctor visit, and then after surgery at 1 year, 2 years, 5 years, and 10 years. The final survey will be completed at your last clinic visit for SCFE.
We are doing this study to find out if a new type of assessment works well for middle-aged and older adults with sickle cell disease (SCD). We want to see if this assessment is useful in detecting changes in health. We hope the assessment can provide useful information to help improve the quality of life for adults with sickle cell disease.
We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.
We are doing this study to learn more about how different factors in pregnancy lead to healthy babies. Specifically, whether factors related to father's health affect the placenta and baby, what part of placental and fetal genes are related to placenta health and baby growth, and to find out the best time to deliver when the mother has gestational diabetes.
If you can join, you will be placed in Part A or Part B based on when you start. In Part A, you will get one of three study medicines: SPY001, SPY002, or SPY003. In Part B, you will get one of these medicines, a mix of two medicines, or a placebo, which does nothing. The study will last about 97 weeks, and you will have around 20 visits or phone calls. During these, doctors will do tests like blood draws, endoscopy with biopsy, heart checks, and x-rays.